Please login to the form below

Not currently logged in
Email:
Password:

Vargatef

This page shows the latest Vargatef news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Opdivo for lung cancer once again

NICE rejects Opdivo for lung cancer once again

NICE says that second-line patients should now be offered docetaxel or Boehringer Ingelheim's Vargatef (nintedanib).

Latest news

More from news
Approximately 4 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics